Back to today’s briefing

Story perspectives

FDA partners to expand estradiol patch supply amid surge

9/4/2026

36 5 Full Breakdown

Summary

Story summary

FDA is collaborating with six manufacturers to boost estradiol patch supply.
Demand surged after the agency removed a boxed warning on estrogen risks.
Sandoz said it allocated additional supplies to meet rising U.S. demand.
Bayer warned of temporary supply constraints for one Climara dose until early 2027.
Viatris announced a new production line and third-party partners to increase output.

1 of 1

Story summary

FDA is collaborating with six manufacturers to boost estradiol patch supply.
Demand surged after the agency removed a boxed warning on estrogen risks.
Sandoz said it allocated additional supplies to meet rising U.S. demand.
Bayer warned of temporary supply constraints for one Climara dose until early 2027.
Viatris announced a new production line and third-party partners to increase output.